Emerging Markets Earnings Roundup: Bayer, Novo Nordisk, Teva (Part 7)

Newer drugs at Bayer helped the bottom line in the third quarter while the world’s top insulin maker Novo Nordisk missed expectations, but held out emerging markets as a bright spot. Teva tussled with analysts on the surprise exit of Jeremy Levin and said that many of the plans during his brief tenure were driven by the board and remain in place.